Antula is established in the Nordics with its own organization.
The acquisition of Antula offers Meda clear growth opportunities, partly through Meda and Antula’s existing prescription-free (OTC) products, and partly through Antula’s pipeline that consists of three to four new products annually.
Through the integration with Meda, several of the products are expected to have potential to become international brands.
Antula’s and Meda’s OTC products will together make up over 20% of Meda’s total sales.
The transaction is subject to standard closing requirements and the approval of the competition authorities. The acquisition of Antula is expected to be completed within a couple of months.